Pleural
Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma
Lung Cancer 2025 May [Link] Ernest Nadal, Paloma Martín-Martorell, Jose Carlos Benítez, Maria Ángeles Sala, Susana Cedrés, Carlos Álvarez, Manuel Dómine, Elia Sais 8, Maria Saigí, Rafael López, Laia Vilà, Bartomeu Massutí, Rosario García-Campelo, Andres Mesas-Ruiz, Amelia Insa, Sílvia Plans-Marín, Sara Hijazo-Pechero, Cristina Muñoz-Pinedo, Jesús Brenes, Mariano Provencio Abstract Objectives: We aimed to evaluate the…
Read MoreCytoplasmic HuR Expression Enhances Chemoresistance in Pleural Mesothelioma Through Increased Expression of CALB2, Promotion of the E2F Pathway, and Suppression of the p53 Pathway
Thoracic Cancer 2025 April [Link] Susumu Kirimura, Morito Kurata, Hironori Ishibashi, Yusuke Taniguchi, Yuko Kinowaki, Keisuke Sugita, Kenichi Okubo Abstract Introduction: Chemotherapy is crucial for treating pleural mesothelioma; however, the outcomes are poor, necessitating an urgent need to study the mechanism of chemotherapy resistance in mesothelioma cells. Human antigen R (HuR), an RNA-binding protein and…
Read MoreRadical hemithorax radiotherapy induces an increase in circulating PD-1+ T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?
Frontiers in Immunology 2025 April 1 [Link] Alberto Revelant, Francesca Gessoni, Marcella Montico, Raja Dhibi, Giulia Brisotto, Mariateresa Casarotto, Martina Zanchetta, Veronica Paduano, Filippo Sperti, Chiara Evangelista, Fabiana Giordari, Valli De Re, Marco Trovò, Emilio Minatel, Maurizio Mascarin, Agostino Steffan, Elena Muraro Abstract Malignant Pleural Mesothelioma (MPM) is an aggressive tumor associated with asbestos exposure,…
Read MoreIncidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy
JTO Clinical & Research Reports 2025 March 10 [Link] Margaret Stalker, Suzanne L Walker, Emily Lebow, Emily Ling-Lin Pai, Alex Watts, Wei-Ting Hwang, Amir Banihashemi, Evan Anderson, Leonid Roshkovan, Sharyn I Katz, Leslie Litzky, Andrew R Haas, Sunil Singhal, Corey J Langer, Keith Cengel, Melina E Marmarelis Abstract Introduction: Immunotherapy (IO) has reported efficacy in…
Read MoreAd-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma
Clinical Cancer Research 2025 April 10 [Link] Hee-Jin Jang, Meera Patel, Daniel Y Wang, Sung Wook Kang, Jong Min Choi, Claire Lee, Monica Vilchis, Ji Seon Shim, Sonali Mitra, Priyanka Ranchod, Allen Kuncheria, William Hudson, Peter Jindra, Veronica Lenge De Rosen, Maheshwari Ramineni, Ernest Ramsay Camp, Farrah Kheradmand, R Taylor Ripley, Shawn S Groth, Hyun-Sung…
Read MoreGenome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesothelioma
Cell Death & Disease 2025 April 3 [Link] Ece Cakiroglu, Sude Eris, Ozden Oz, Gökhan Karakülah, Serif Senturk Abstract Malignant pleural mesothelioma (MPM) is a rare yet highly aggressive malignancy with a severe prognosis. Compounded by the lack of effective treatment modalities, MPM remains a formidable health challenge. Therefore, the identification of actionable liabilities is…
Read MoreUtility and limitations of Merlin immunohistochemistry for mesothelioma diagnosis in tissue sections and cell blocks
Annals of Diagnostic Pathology 2025 August [Link] Kazuki Nabeshima, Makoto Hamasaki, Tomomi Furukawa, Shinji Matsumoto, Katsumi Takizawa, Makiko Adachi, Yuko Goto Abstract Distinguishing pleural mesothelioma (PM) from reactive mesothelial proliferations (RMP) can be challenging. In such cases, immunohistochemistry (IHC)-detected BAP1 or MTAP loss and FISH-detected CDKN2A homozygous deletion are effective. Merlin is the protein product…
Read MoreDiagnostic utility of pleuroscopic guided pleural biopsy versus pleural fluid cell block in the diagnosis of malignant pleural effusion
The Medical Journal of Malaysia 2025 March [Link] B H Ng, H J Low, N N N Abeed, C I Soo, M I Azmi, N S Sharil, R A Osman, M F A Hamid, A Y L Ban Abstract Introduction: Pleural biopsy using flex-rigid pleuroscopy or pleural effusion cell block analysis is useful for diagnosing…
Read MoreEx-Vivo Drug-Sensitivity Testing to Predict Clinical Response in Non-Small Cell Lung Cancer and Pleural Mesothelioma: A Systematic Review and Narrative Synthesis
Cancers 2025 March 14 [Link] Jenny Zipprick, Enes Demir, Hanna Krynska, Sıla Köprülüoğlu, Katharina Strauß, Marcus Skribek, Rita Hutyra-Gram Ötvös, Annica K B Gad, Katalin Dobra Abstract Background/objectives: Non-small cell lung cancer and pleural mesothelioma are among the most lethal and therapy-resistant tumors in humans. These tumors are diagnosed late, frequently present pleural effusion and…
Read MoreDNA methylation-regulated HLA-C expression modulates immune responses and metabolic alterations to influence prognosis in mesothelioma
Cancer Immunology, Immunotherapy 2025 March 25 [Link] Huilin Zhang, Luanxue Yu, Yunqing Guo, Jiawei Ming, Zhenying Guo Abstract Background: Malignant mesothelioma is a highly aggressive cancer with a poor prognosis and limited therapeutic options. The tumor microenvironment (TME) plays a pivotal role in driving tumor progression, with immune cells influencing disease outcomes. However, the molecular…
Read More